Rodman & Renshaw Downgrades Acorda Therapeutics (ACOR) to Market Underperform
More News related to ACOR
- Acorda Therapeutics to Present at the 21st Annual Piper Jaffray Health Care Conference
- Acorda Therapeutics to Present at the Lazard Capital Markets 6th Annual Healthcare Conference
- Acorda Therapeutic (ACOR) volatility at 55 into extension of PDUFA
- Acorda Thera (ACOR) Posts Q3 Loss of $0.51, 8c Better than Estimates
- Acorda Therapeutics Reports Third Quarter 2009 Financial Results
More News related to Downgrades
- Wunderlich Securities Downgrades Gran Tierra Energy (GTE) to Hold
- Stephens Downgrades Benihana (BNHN) to Equalweight
- UBS Downgrades NRG Energy (NRG) to Neutral; Cuts Target to $26
- Citi Cuts Lukoil (LUKOY) to Hold
- RBC Upgrades Diamond Rock (DRH) to Outperform, Downgrades Hospitality Properties (HPT) to Sector Perform
Rodman & Renshaw downgrades Acorda Therapeutics (Nasdaq: ACOR) to Market Underperform.
Click here to see all the analyst upgrades/downgrades on shares of Acorda.
Acorda Therapeutics, Inc., a biopharmaceutical company, engages in the identification, development, and commercialization of various therapies for the improvement of neurological functions in people with multiple sclerosis (MS), spinal cord injury, and other disorders of the central nervous system in the United States.
Related Categories
DowngradesStocks Mentioned
+0.07Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
